{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:11:39Z","timestamp":1768320699367,"version":"3.49.0"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3,15]]},"DOI":"10.1093\/infdis\/jix015","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T04:07:26Z","timestamp":1483675646000},"page":"920-927","source":"Crossref","is-referenced-by-count":33,"title":["Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment\u2013Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide"],"prefix":"10.1093","volume":"215","author":[{"given":"Nicolas A.","family":"Margot","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rima","family":"Kulkarni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Porter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael E.","family":"Abram","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Callebaut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,1,30]]},"reference":[{"key":"key\n\t\t\t\t20170522162603_CIT0001","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.coviro.2016.03.004","article-title":"Current status and prospects of HIV treatment","volume":"18","year":"2016","journal-title":"Curr Opin Virol"},{"key":"key\n\t\t\t\t20170522162603_CIT0002","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1126\/science.2479983","article-title":"Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)","volume":"246","year":"1989","journal-title":"Science"},{"key":"key\n\t\t\t\t20170522162603_CIT0003","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","year":"2015","journal-title":"Top Antivir Med"},{"key":"key\n\t\t\t\t20170522162603_CIT0004","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.3390\/v6104095","article-title":"Current perspectives on HIV-1 antiretroviral drug resistance","volume":"6","year":"2014","journal-title":"Viruses"},{"key":"key\n\t\t\t\t20170522162603_CIT0005","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1056\/NEJM199304223281605","article-title":"Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522162603_CIT0006","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1086\/644505","article-title":"Transmission of drug-resistant HIV-1 is stabilizing in Europe","volume":"200","year":"2009","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0007","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1093\/jac\/dkt238","article-title":"National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001\u20132011","volume":"68","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170522162603_CIT0008","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1086\/432916","article-title":"Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management","volume":"192","author":"SPREAD Programme","year":"2005","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0009","doi-asserted-by":"crossref","first-page":"e21189","DOI":"10.1371\/journal.pone.0021189","article-title":"Transmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral load","volume":"6","year":"2011","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522162603_CIT0010","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1128\/JVI.02712-06","article-title":"The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions","volume":"81","year":"2007","journal-title":"J Virol"},{"key":"key\n\t\t\t\t20170522162603_CIT0011","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1074\/jbc.M308806200","article-title":"Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations","volume":"279","year":"2004","journal-title":"J Biol Chem"},{"key":"key\n\t\t\t\t20170522162603_CIT0012","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1093\/infdis\/jiq167","article-title":"Differential persistence of transmitted HIV-1 drug resistance mutation classes","volume":"203","year":"2011","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0013","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12977-014-0105-9","article-title":"Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity","volume":"11","author":"SPREAD Programme","year":"2014","journal-title":"Retrovirology"},{"key":"key\n\t\t\t\t20170522162603_CIT0014","doi-asserted-by":"crossref","first-page":"e1004722","DOI":"10.1371\/journal.ppat.1004722","article-title":"Persistence of transmitted HIV-1 drug resistance mutations associated with fitness costs and viral genetic backgrounds","volume":"11","author":"Swiss HIV Cohort Study (SHCS)","year":"2015","journal-title":"PLoS Pathog"},{"key":"key\n\t\t\t\t20170522162603_CIT0015","doi-asserted-by":"crossref","first-page":"13907","DOI":"10.1073\/pnas.241300698","article-title":"Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons","volume":"98","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20170522162603_CIT0016","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1001\/jama.279.24.1984","article-title":"Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel","volume":"279","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170522162603_CIT0017","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1086\/375597","article-title":"Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel","volume":"37","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0018","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1177\/135965350400900619","article-title":"Updated European recommendations for the clinical use of HIV drug resistance testing","volume":"9","year":"2004","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522162603_CIT0019","author":"US Department of Health and Human Services"},{"key":"key\n\t\t\t\t20170522162603_CIT0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/AAC.42.2.269","article-title":"A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs","volume":"42","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522162603_CIT0021","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","article-title":"A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1","volume":"44","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522162603_CIT0022","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1097\/QAD.0000000000000169","article-title":"Week 48 results from a randomized clinical trial of rilpivirine\/emtricitabine\/tenofovir disoproxil fumarate vs. efavirenz\/emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults","volume":"28","year":"2014","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522162603_CIT0023","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"903 Study Group","year":"2004","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20170522162603_CIT0024","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Study 934 Group","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170522162603_CIT0025","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/infdis\/jit122","article-title":"Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine\/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results","volume":"208","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0026","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1016\/S0140-6736(12)60918-0","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial","volume":"379","author":"GS-236-0103 Study Team","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522162603_CIT0027","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1016\/S0140-6736(12)60917-9","article-title":"Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks","volume":"379","author":"GS-US-236-0102 Study Team","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522162603_CIT0028","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"GS-US-292-0104\/0111 Study Team","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170522162603_CIT0029","first-page":"1","article-title":"Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a phase IIIb, open-label single-arm trial","volume":"11","year":"2014","journal-title":"AIDS Res Ther"},{"key":"key\n\t\t\t\t20170522162603_CIT0030","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0b013e3283427dcb","article-title":"Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy","volume":"25","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20170522162603_CIT0031","doi-asserted-by":"crossref","first-page":"e4724","DOI":"10.1371\/journal.pone.0004724","article-title":"Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update","volume":"4","year":"2009","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170522162603_CIT0032","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/009286151104500309","article-title":"A meta-analysis to assess the FDA DAVP\u2019s TLOVR algorithm in HIV submissions","volume":"45","year":"2011","journal-title":"Drug Inf J"},{"key":"key\n\t\t\t\t20170522162603_CIT0034","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1086\/381784","article-title":"Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients","volume":"189","year":"2004","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1080\/15284336.2016.1142731","article-title":"Rare emergence of drug resistance in HIV-1 treatment-naive patients after 48 weeks of treatment with elvitegravir\/cobicistat\/emtricitabine\/tenofovir alafenamide","volume":"17","year":"2016","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20170522162603_CIT0036","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/QAI.0b013e3181b05f7c","article-title":"Development of HIV-1 drug resistance through 144 weeks in antiretroviral-na\u00efve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine\/zidovudine and efavirenz in study GS-01-934","volume":"52","author":"Study 934 Team","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522162603_CIT0037","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1468-1293.2006.00404.x","article-title":"Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in study 903","volume":"7","author":"Study 903 Team","year":"2006","journal-title":"HIV Med"},{"key":"key\n\t\t\t\t20170522162603_CIT0038","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1097\/QAI.0000000000000017","article-title":"Characterization of HIV-1 drug resistance development through week 48 in antiretroviral naive subjects on rilpivirine\/emtricitabine\/tenofovir DF or efavirenz\/emtricitabine\/tenofovir DF in the STaR study (GS-US-264-0110)","volume":"65","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522162603_CIT0039","doi-asserted-by":"crossref","first-page":"317","DOI":"10.3851\/IMP2885","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus efavirenz\/emtricitabine\/tenofovir DF in antiretroviral-naive patients","volume":"20","year":"2015","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20170522162603_CIT0040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1310\/hct1504-218","article-title":"Week 144 resistance analysis of elvitegravir\/cobicistat\/emtricitabine\/tenofovir DF versus atazanavir+ritonavir+emtricitabine\/tenofovir DF in antiretroviral-na\u00efve patients","volume":"15","year":"2014","journal-title":"HIV Clin Trials"},{"key":"key\n\t\t\t\t20170522162603_CIT0041","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/cid\/civ963","article-title":"Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe","volume":"62","author":"SPREAD Program","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0042","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1093\/cid\/ciw382","article-title":"Transmitted HIV drug resistance is high and longstanding in Metropolitan Washington, DC","volume":"63","year":"2016","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0043","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/QAI.0b013e31817bbe93","article-title":"The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutation","volume":"48","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t20170522162603_CIT0044","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1093\/infdis\/jit310","article-title":"Origin of minority drug-resistant HIV-1 variants in primary HIV-1 infection","volume":"208","author":"Swiss HIV Cohort Study","year":"2013","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t20170522162603_CIT0045","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1128\/AAC.00068-10","article-title":"Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside\/nucleotide-resistant HIV","volume":"54","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522162603_CIT0046","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.1128\/AAC.01195-13","article-title":"In vitro cross-resistance profile of nucleoside reverse transcriptase inhibitor (NRTI) BMS-986001 against known NRTI resistance mutations","volume":"57","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170522162603_CIT0047","doi-asserted-by":"crossref","first-page":"10747","DOI":"10.1128\/JVI.01827-07","article-title":"Minority human immunodeficiency virus type 1 variants in antiretroviral-naive persons with reverse transcriptase codon 215 revertant mutations","volume":"82","year":"2008","journal-title":"J Virol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/215\/6\/920\/17412624\/jix015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T21:06:04Z","timestamp":1658351164000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article-lookup\/doi\/10.1093\/infdis\/jix015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,30]]},"references-count":46,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,1,30]]},"published-print":{"date-parts":[[2017,3,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jix015","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,30]]}}}